# US 10,987,374 B2 · Composition for promoting production of immunostimulatory factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,987,374 B2
- Document ID: US10987374B2
- Status: Granted
- Kind: B2
- Application number: 16/322,626
- Filed: 2017-07-31
- Published: 2019-09-26
- Granted: 2021-04-27
- Earliest claimed: 2016-08-02
- Assignees: Kyoto University
- Applicants: Kyoto University
- Inventors: Takashi Fujita; Hiroki Kato; Tetsuya Nakazaki
- Web page: https://patentgrep.com/patent/US10987374B2

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A23L 33/13: Nucleic acids or derivatives thereof (A23L33/145 takes precedence)
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2720/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

According to the present invention, various diseases, such as viral diseases, cancer, and multiple sclerosis, can be prevented and improved by using an immunostimulatory factor production-promoting composition comprising genomic double-stranded RNA of a plant-derived endornavirus.

## Claims

### Claim 1

A method for promoting immunostimulatory factor production in an animal or human, comprising administering a composition comprising a genomic double-stranded RNA of a plant-derived endornavirus to the animal or human.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the plant is a capsicum plant, a rice plant, or a Vicia plant.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the genomic double-stranded RNA has a length of 8 to 20 kbp.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the genomic double-stranded RNA is linear.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition is a pharmaceutical composition.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition is an intranasal preparation.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition is an oral preparation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition is a food composition.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the animal or human has a viral infection.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the animal or human has an RNA viral infection.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the composition is used as an adjuvant.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the animal or human has cancer.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the plant is Capsicum annuum Kyousuzu.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the plant is Oryza sativa Koshihikari.